HALTING PANCREATIC CANCER IS URGENT
INCREASE FUNDING FOR THE NIH AND NCI TO CONTINUE LIFESAVING RESEARCH

A continued and robust investment in research funding at the National Institutes of Health (NIH) and National Cancer Institute (NCI) is needed to provide pancreatic cancer patients more moments that matter.

YOU CAN’T IGNORE THESE FACTS

• Pancreatic cancer is one of the deadliest major cancers with the lowest survival rate at just 9 percent.¹
• It is the 3rd leading cause of cancer-related death in the U.S.¹
• There is no early detection method.
• There are few effective treatment options.

“THE FEDERAL FUNDING THAT I’VE RECEIVED IS CRITICAL TO SUSTAIN THE LAB, ALLOW THE RESEARCH TO CONTINUE AND HELP ME FOCUS ON THE SCIENCE.”

— Cosimo Commisso, PhD
Assistant Professor, Sanford Burnham Prebys Medical Discovery Institute
Pancreatic Cancer Researcher

NIH AND NCI FUNDING IS CRITICAL TO ACCELERATING PANCREATIC CANCER DISCOVERIES

NIH and NCI funding supports the basic science research necessary to devise better early detection strategies and more effective treatments.

NIH funding is critical to the nation’s economy and job creation, contributing to:

- Nearly $74 billion in economic activity²
- 433,000 jobs²

More NIH and NCI funding correlates with better survival:

- NCI funding for pancreatic cancer³
- 5-year survival rate for pancreatic cancer⁴

Tomorrow’s moments depend on today’s investments in lifesaving cancer research.

THE PANCREATIC CANCER ACTION NETWORK URGES THE 116TH CONGRESS TO MAKE MORE MOMENTS MATTER:

Support $41.6 billion for the NIH in FY 2020, including $6.5 billion for the NCI.

2. NIH’s Role in Sustaining the U.S. Economy 2019 Update, United for Medical Research (accessed: May 2019).